{"id":63849,"date":"2026-04-23T22:28:35","date_gmt":"2026-04-23T14:28:35","guid":{"rendered":"https:\/\/flcube.com\/?p=63849"},"modified":"2026-04-23T22:28:36","modified_gmt":"2026-04-23T14:28:36","slug":"hengrui-pharmaceuticals-reports-strong-q1-2026-results-with-12-98-revenue-growth-and-multiple-new-drug-approvals","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63849","title":{"rendered":"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>)<\/strong> has released its <strong>first quarter 2026 financial results<\/strong>, reporting <strong>total revenues of RMB 8.141 billion (USD 1.19 billion)<\/strong>, representing a <strong>12.98% year-over-year (YOY) increase<\/strong>, and <strong>net profits of RMB 2.282 billion (USD 330 million)<\/strong>, up <strong>21.78% YOY<\/strong>. The company&#8217;s <strong>innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million)<\/strong>, accounting for <strong>61.69% of total pharmaceutical sales<\/strong>, while <strong>R&amp;D investment reached RMB 2.224 billion (USD 323 million)<\/strong>. The quarter also saw <strong>three major regulatory approvals<\/strong> for proprietary Class 1 innovative drugs across oncology and hematology indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenues<\/strong><\/td><td>RMB 8.141B (USD 1.19B)<\/td><td>+12.98%<\/td><\/tr><tr><td><strong>Net Profits<\/strong><\/td><td>RMB 2.282B (USD 330M)<\/td><td>+21.78%<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>RMB 2.224B (USD 323M)<\/td><td>Significant increase<\/td><\/tr><tr><td><strong>Innovative Drug Sales<\/strong><\/td><td>RMB 4.526B (USD 660M)<\/td><td>+25.75%<\/td><\/tr><tr><td><strong>Oncology Product Sales<\/strong><\/td><td>RMB 3.313B (USD 481M)<\/td><td>+11.63%<\/td><\/tr><tr><td><strong>Non-Oncology Product Sales<\/strong><\/td><td>RMB 1.213B (USD 176M)<\/td><td>+92.13%<\/td><\/tr><tr><td><strong>Out-licensing Revenue<\/strong><\/td><td>RMB 787M (USD 115M)<\/td><td>Strong contribution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones-amp-pipeline-advancement\">Regulatory Milestones &amp; Pipeline Advancement<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reltirafusp \u03b1 Approval:<\/strong> World&#8217;s first approved <strong>anti-PD-L1\/TGF-\u03b2RII bispecific antibody (BsAb) fusion protein<\/strong> received marketing approval for <strong>first-line treatment of locally advanced unresectable, recurrent or metastatic PD-L1-positive (CPS \u2265 1) gastric or gastroesophageal junction adenocarcinoma<\/strong> in combination with fluoropyrimidine and platinum-based agents<\/li>\n\n\n\n<li><strong>Trastuzumab Rezetecan Expansion:<\/strong> <strong>HER2 ADC Class 1 innovative drug<\/strong> secured additional indication approval for <strong>adult patients with locally advanced or metastatic HER2-positive breast cancer<\/strong> who have received one or more prior anti-HER2 therapies<\/li>\n\n\n\n<li><strong>Hetrombopag Olamine Indication:<\/strong> <strong>Class 1 innovative drug<\/strong> gained approval for use in <strong>combination with immunosuppressive therapy for newly diagnosed severe aplastic anemia (SAA)<\/strong> in patients aged 15 years and older<\/li>\n\n\n\n<li><strong>Commercial Impact:<\/strong> These approvals significantly expand Hengrui&#8217;s addressable market across gastrointestinal oncology, breast cancer, and rare hematological disorders<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-segment-analysis\">Business Segment Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Q1 2026 Sales<\/th><th>YOY Growth<\/th><th>Strategic Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Innovative Drugs<\/strong><\/td><td>RMB 4.526B<\/td><td>+25.75%<\/td><td>61.69% of total pharma sales; primary growth driver<\/td><\/tr><tr><td><strong>Oncology Products<\/strong><\/td><td>RMB 3.313B<\/td><td>+11.63%<\/td><td>73.20% of innovative drug sales; established franchise<\/td><\/tr><tr><td><strong>Non-Oncology Products<\/strong><\/td><td>RMB 1.213B<\/td><td>+92.13%<\/td><td>Rapid expansion into new therapeutic areas<\/td><\/tr><tr><td><strong>Out-licensing Revenue<\/strong><\/td><td>RMB 787M<\/td><td>Strong performance<\/td><td>Validates global partnership strategy and asset quality<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>RMB 2.224B<\/td><td>27.3% of revenue<\/td><td>Demonstrates commitment to innovation pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>Hengrui&#8217;s Q1 2026 performance demonstrates the successful execution of its dual strategy: <strong>accelerating commercial momentum<\/strong> in established franchises while <strong>expanding into new therapeutic areas<\/strong> through innovative drug development. The <strong>92.13% growth in non-oncology products<\/strong> highlights the company&#8217;s successful diversification beyond its traditional oncology stronghold, reducing therapeutic concentration risk.<\/p>\n\n\n\n<p>The <strong>three new regulatory approvals<\/strong> represent significant milestones that validate Hengrui&#8217;s scientific innovation capabilities and expand its commercial footprint. <strong>Reltirafusp \u03b1<\/strong> as the world&#8217;s first anti-PD-L1\/TGF-\u03b2RII bispecific antibody positions Hengrui at the forefront of next-generation immuno-oncology, while the <strong>trastuzumab rezetecan<\/strong> expansion strengthens its position in the competitive HER2-positive breast cancer market.<\/p>\n\n\n\n<p>The substantial <strong>R&amp;D investment of RMB 2.224 billion<\/strong> (27.3% of revenue) underscores Hengrui&#8217;s commitment to maintaining a robust innovation pipeline despite strong current commercial performance. This disciplined approach to reinvestment ensures sustainable long-term growth and competitive differentiation in China&#8217;s increasingly sophisticated pharmaceutical market.<\/p>\n\n\n\n<p>The <strong>RMB 787 million in out-licensing revenue<\/strong> demonstrates the global recognition of Hengrui&#8217;s asset quality and validates its international partnership strategy. Such collaborations provide non-dilutive funding for continued R&amp;D while expanding global market access for Hengrui&#8217;s innovative therapies.<\/p>\n\n\n\n<p>From a profitability perspective, the <strong>21.78% net profit growth<\/strong> significantly outpacing revenue growth reflects operational leverage, improved product mix toward higher-margin innovative drugs, and effective cost management across the organization.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, regulatory developments, and business strategy. Actual results may differ due to regulatory decisions, competitive dynamics, market adoption rates, and economic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600276_20260423_22NN.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260423_22NN.\"><\/object><a id=\"wp-block-file--media-b414301f-f482-45cc-8fc0-1aacef412ba9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600276_20260423_22NN.pdf\">600276_20260423_22NN<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600276_20260423_22NN.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b414301f-f482-45cc-8fc0-1aacef412ba9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63851,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,2586,4228,852],"class_list":["post-63849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026 financial results, reporting total revenues of RMB 8.141 billion (USD 1.19 billion), representing a 12.98% year-over-year (YOY) increase, and net profits of RMB 2.282 billion (USD 330 million), up 21.78% YOY. The company&#039;s innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million), accounting for 61.69% of total pharmaceutical sales, while R&amp;D investment reached RMB 2.224 billion (USD 323 million). The quarter also saw three major regulatory approvals for proprietary Class 1 innovative drugs across oncology and hematology indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63849\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026 financial results, reporting total revenues of RMB 8.141 billion (USD 1.19 billion), representing a 12.98% year-over-year (YOY) increase, and net profits of RMB 2.282 billion (USD 330 million), up 21.78% YOY. The company&#039;s innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million), accounting for 61.69% of total pharmaceutical sales, while R&amp;D investment reached RMB 2.224 billion (USD 323 million). The quarter also saw three major regulatory approvals for proprietary Class 1 innovative drugs across oncology and hematology indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63849\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T14:28:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T14:28:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2307.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals\",\"datePublished\":\"2026-04-23T14:28:35+00:00\",\"dateModified\":\"2026-04-23T14:28:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849\"},\"wordCount\":607,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2307.webp\",\"keywords\":[\"Finanical Reports\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63849#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63849\",\"name\":\"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2307.webp\",\"datePublished\":\"2026-04-23T14:28:35+00:00\",\"dateModified\":\"2026-04-23T14:28:36+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026 financial results, reporting total revenues of RMB 8.141 billion (USD 1.19 billion), representing a 12.98% year-over-year (YOY) increase, and net profits of RMB 2.282 billion (USD 330 million), up 21.78% YOY. The company's innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million), accounting for 61.69% of total pharmaceutical sales, while R&D investment reached RMB 2.224 billion (USD 323 million). The quarter also saw three major regulatory approvals for proprietary Class 1 innovative drugs across oncology and hematology indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63849\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2307.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2307.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63849#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026 financial results, reporting total revenues of RMB 8.141 billion (USD 1.19 billion), representing a 12.98% year-over-year (YOY) increase, and net profits of RMB 2.282 billion (USD 330 million), up 21.78% YOY. The company's innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million), accounting for 61.69% of total pharmaceutical sales, while R&D investment reached RMB 2.224 billion (USD 323 million). The quarter also saw three major regulatory approvals for proprietary Class 1 innovative drugs across oncology and hematology indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63849","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026 financial results, reporting total revenues of RMB 8.141 billion (USD 1.19 billion), representing a 12.98% year-over-year (YOY) increase, and net profits of RMB 2.282 billion (USD 330 million), up 21.78% YOY. The company's innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million), accounting for 61.69% of total pharmaceutical sales, while R&D investment reached RMB 2.224 billion (USD 323 million). The quarter also saw three major regulatory approvals for proprietary Class 1 innovative drugs across oncology and hematology indications.","og_url":"https:\/\/flcube.com\/?p=63849","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-23T14:28:35+00:00","article_modified_time":"2026-04-23T14:28:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2307.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63849#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63849"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals","datePublished":"2026-04-23T14:28:35+00:00","dateModified":"2026-04-23T14:28:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63849"},"wordCount":607,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63849#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2307.webp","keywords":["Finanical Reports","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63849#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63849","url":"https:\/\/flcube.com\/?p=63849","name":"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63849#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63849#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2307.webp","datePublished":"2026-04-23T14:28:35+00:00","dateModified":"2026-04-23T14:28:36+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026 financial results, reporting total revenues of RMB 8.141 billion (USD 1.19 billion), representing a 12.98% year-over-year (YOY) increase, and net profits of RMB 2.282 billion (USD 330 million), up 21.78% YOY. The company's innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million), accounting for 61.69% of total pharmaceutical sales, while R&D investment reached RMB 2.224 billion (USD 323 million). The quarter also saw three major regulatory approvals for proprietary Class 1 innovative drugs across oncology and hematology indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63849#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63849"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63849#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2307.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2307.webp","width":1080,"height":608,"caption":"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63849#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2307.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63849"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63849\/revisions"}],"predecessor-version":[{"id":63852,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63849\/revisions\/63852"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63851"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}